Novartis AG Common Stock (NY:NVS)

139.58 -1.42 (-1.01%)

Delayed Quote Updated: 10:51 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

59 60 Next >

Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030

November 14, 2023

EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END

Via FinancialNewsMedia

Verve Loses A Third Of Its Value As Safety Concerns Plague Its Gene-Editing Drug ↗

November 13, 2023

Patients had big decreases in LDL cholesterol. But there were some side effects.

Via Investor's Business Daily

How Is The Market Feeling About Novartis? ↗

November 10, 2023

Via Benzinga

3 Spectacular High-Yield Dividend Stocks to Buy in November ↗

November 05, 2023

Income investors should find plenty to like with these stocks.

Via The Motley Fool

Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week ↗

October 30, 2023

S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week.

Via Benzinga

Topics Economy Stocks

Novartis Hikes Its Earnings Outlook For The Third Time This Year ↗

October 24, 2023

The company also beat third-quarter expectations after spinning off its Sandoz unit.

Via Investor's Business Daily

Earnings Outlook For Novartis ↗

October 23, 2023

Via Benzinga

Get Ready for Next Generation of Diabetes, Weight-Management Drugs

November 01, 2023

Via Investor Brand Network

Get Ready for Next Generation of Diabetes, Weight-Management Drugs

November 01, 2023

EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:JNJ),(NYSE:SNY),(NASDAQ:AMGN),(NYSE:NVS) EQNX::TICKER_END

Via FinancialNewsMedia

Novartis' Rare Kidney Disease Candidate Aces Late-Stage Study ↗

October 30, 2023

Novartis AG (NYSE: NVS) released topline results from the interim analysis of the ongoing pivotal Phase 3 ALIGN study of atrasentan in patients with IgA nephropathy (IgAN). IgAN is a major cause of...

Via Benzinga

Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More ↗

October 28, 2023

The U.S.

Via Benzinga

3 No-Brainer Stocks to Buy for Under $100 Right Now ↗

October 28, 2023

A couple of these stocks might not be available for under $100 for too much longer.

Via The Motley Fool

2 Green Flags and 1 Red Flag for Novartis Stock ↗

October 27, 2023

The Swiss pharmaceutical company just posted strong Q3 numbers and is going through some big changes.

Via The Motley Fool

7 Undervalued Stocks to Buy Before Everyone Else ↗

October 26, 2023

Buy these undervalued stocks while they trade at a significant discount compared to their intrinsic valuations.

Via InvestorPlace

Sanofi Stock Relative Strength Rating Jumps To 84: One To Watch ↗

October 24, 2023

Additionally, Sanofi stock has a decent 83 Composite Rating out of 99, and an 80 Earnings Per Share Rating.

Via Investor's Business Daily

Novartis Ag (NVS) Q3 2023 Earnings Call Transcript ↗

October 24, 2023

NVS earnings call for the period ending September 30, 2023.

Via The Motley Fool

Topics Earnings

Nano Pharmaceutical Market Next Big Move: Major Giants Abbott Laboratories, Bayer AG, Novartis AG, GlaxoSmithKline ↗

October 24, 2023

According to HTF Market Intelligence, the Global Nano Pharmaceutical market is segmented by Application (Oncology, Cardiovascular/Physiology, Antiinflammatory/Immunology, Neurology, Anti-Infective,...

Via SBWire

Avenue Z Hires Leading Digital Media and Technology Executive David Corchado to Lead Team in Global Strategy

October 24, 2023

--News Direct--

Via News Direct

US Stock Futures Surge Ahead Of Microsoft, Google Earnings: Analyst Says 'Magnificent Seven' Unlikely To See Tesla-Like Volatility After Results ↗

October 24, 2023

Buoyed by earnings optimism, stocks appear on track for a positive open on Tuesday after the tech-heavy Nasdaq Composite Index snapped a four-day losing streak in the previous session. The uptick in...

Via Benzinga

Topics Bonds Stocks

Novartis Q3: Earnings Beat, Raised Operating Profit Outlook & More ↗

October 24, 2023

Novartis AG (NYSE: NVS) reported

Via Benzinga

Topics Earnings

Amazon, Alphabet, Meta, Intel Q3 Earnings This Week: Will Mega-Caps Shatter Forecasts And Revive Market? ↗

October 23, 2023

Factset data indicates that out of the 17% of the S&P 500 companies that have reported so far, 73% have reported positive EPS surprises.

Via Benzinga

Topics Stocks

7 Healthcare Stocks to invest in for a Healthy Future ↗

October 20, 2023

Considering today's economic uncertainty and market turns, healthcare stocks may be one of the few winning sectors. Here are the winners.

Via InvestorPlace

2 Biotech Stocks That Could Make You Richer ↗

October 17, 2023

These two well-known drugmakers still have some growth fuel in their seemingly empty tanks.

Via The Motley Fool

3 Unstoppable Stocks to Buy and Hold for Decades ↗

October 17, 2023

These stocks can be pillars for your long-term portfolio, and investing in all three offers excellent diversification.

Via The Motley Fool

Why Top 1% Biotech MoonLake Just Surged Within Striking Distance Of A Breakout ↗

October 16, 2023

MoonLake says it's skin-disease treatment showed improved promise in a 24-week testing update.

Via Investor's Business Daily

Weight Loss Drugs Market Size, Share, Growth, Trends, Analysis 2028

October 13, 2023

Get an extensive Weight Loss Drugs Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.

Via SBWire

Antiparasitic Drugs Market to See Major Growth by 2023-2030 : Arbor Pharmaceuticals, GlaxoSmithKline, Cipla

October 11, 2023

Get an extensive Antiparasitic Drugs Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.

Via SBWire

RayzeBio Is A New Contender in Radiopharmaceutical Arena, Will Attract Prominent Entities: JP Morgan ↗

October 10, 2023

JP Morgan has initiated coverage on RayzeBio Inc (NASDAQ: RYZB), representing a pure-play opportunity in the radiopharmaceutical space.

Via Benzinga

Cancer Immunotherapies Market Set for More Growth : American Cancer Society, WebMD, Eli Lily and Company

October 10, 2023

Get an extensive Cancer Immunotherapies Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.

Via SBWire

AbbVie Stock Moves Higher With Rising Relative Strength ↗

October 10, 2023

A Relative Strength Rating upgrade for AbbVie shows improving technical performance. Will it continue?

Via Investor's Business Daily

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.